Skin rash signifies improved outcomes for lung and pancreatic cancer patientsThe appearance of a rash in patients suffering from cancer and treated with erlotinib (Tarceva) is strongly associated with longer survival, as per researchers from the drug’s developer, OSI Pharmaceuticals, Inc.

This is not the first time that rashes have been linked with a survival advantage in regard to a class of drugs, EGFR (epidermal growth factor receptor) inhibitors, which include erlotinib, cetuximab, panitumumab and others designed for blocking overproduction of EGFR but this was hailed as the most detailed analysis to date.

The study was published in the July 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research.